Halozyme (HALO) Says Prandial Insulin + rHuPH20 Phase 2 Met Primary Endpoint in Type 1 Diabetes Patients
Go back to Halozyme (HALO) Says Prandial Insulin + rHuPH20 Phase 2 Met Primary Endpoint in Type 1 Diabetes Patients| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 106.96 -0.66 (0.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $107.62 | 52 Week High | $18.39 | |||
| Open | $106.41 | 52 Week Low | $6.96 | |||
| Day High | $107.44 | P/E | N/A | |||
| Day Low | $105.20 | EPS | $-0.58 | |||
| Volume | 420,389 | |||||
